ADC Therapeutics SA (ADCT)

USD 1.21

(-0.82%)

Total Assets Summary of ADC Therapeutics SA

ADC Therapeutics SA's latest annual total assets in 2023 was 354.78 Million USD , down -32.95% from previous year.
ADC Therapeutics SA's latest quarterly total assets in 2024 Q2 was 371.77 Million USD , up 20.72% from previous quarter.
ADC Therapeutics SA reported annual total assets of 529.16 Million USD in 2022, down -14.37% from previous year.
ADC Therapeutics SA reported annual total assets of 617.97 Million USD in 2021, up 20.3% from previous year.
ADC Therapeutics SA reported quarterly total assets of 371.77 Million USD for 2024 Q2, up 20.72% from previous quarter.
ADC Therapeutics SA reported quarterly total assets of 466.9 Million USD for 2023 Q3, down -7.96% from previous quarter.

Annual Total Assets Chart of ADC Therapeutics SA (2023 - 2016)

Historical Annual Total Assets of ADC Therapeutics SA (2023 - 2016)

Year	Total Assets	Total Assets Growth
2023	354.78 Million USD	-32.95%
2022	529.16 Million USD	-14.37%
2021	617.97 Million USD	20.3%
2020	513.69 Million USD	273.1%
2019	137.68 Million USD	-8.55%
2018	150.55 Million USD	-44.64%
2017	271.94 Million USD	75.36%
2016	155.07 Million USD	0.0%

Year	Total Assets	Total Assets Growth
2024 Q1	307.96 Million USD	-13.2%
2024 Q2	371.77 Million USD	20.72%
2023 Q3	466.9 Million USD	-7.96%
2023 Q1	467.67 Million USD	-11.62%
2023 FY	354.78 Million USD	-32.95%
2023 Q4	354.78 Million USD	-24.01%
2023 Q2	507.3 Million USD	8.47%
2022 Q1	581.88 Million USD	-5.84%
2022 FY	529.16 Million USD	-14.37%
2022 Q4	529.16 Million USD	-0.49%
2022 Q3	531.75 Million USD	2.17%
2022 Q2	520.46 Million USD	-10.56%
2021 Q2	464.38 Million USD	0.58%
2021 Q3	637.97 Million USD	37.38%
2021 Q4	617.97 Million USD	-3.14%
2021 FY	617.97 Million USD	20.3%
2021 Q1	461.7 Million USD	-10.12%
2020 Q2	373.84 Million USD	0.0%
2020 Q3	521.52 Million USD	39.5%
2020 Q1	- USD	-100.0%
2020 FY	513.69 Million USD	273.1%
2020 Q4	513.69 Million USD	-1.5%
2019 Q2	200.83 Million USD	0.0%
2019 Q4	137.68 Million USD	0.0%
2019 FY	137.68 Million USD	-8.55%
2019 Q1	- USD	-100.0%
2018 Q1	- USD	0.0%
2018 Q3	150.55 Million USD	0.0%
2018 Q4	150.55 Million USD	0.0%
2018 FY	150.55 Million USD	-44.64%
2017 FY	271.94 Million USD	75.36%
2016 FY	155.07 Million USD	0.0%

Peer Total Assets Comparison of ADC Therapeutics SA

Name	Total Assets	Total Assets Difference
Alto Neuroscience, Inc.	86.62 Million USD	-309.547%
Annovis Bio, Inc.	10.2 Million USD	-3375.439%
Biohaven Pharmaceutical Holding Company Ltd.	513.21 Million USD	30.87%
Ginkgo Bioworks Holdings, Inc.	1.66 Billion USD	78.696%
Nuvation Bio Inc.	621.48 Million USD	42.914%
Nuvation Bio Inc.	621.48 Million USD	42.914%
Arcus Biosciences, Inc.	1.09 Billion USD	67.6%
Zymeworks Inc.	580.88 Million USD	38.923%